XML 21 R6.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Cash flows from operating activities    
Net loss $ (626,682) $ (1,783,279)
Adjustments to reconcile net loss to net cash used in operating activities:    
Change in fair value of collateral securing employee advances 2,143 6,858
Depreciation and amortization 184,320 172,167
Stock-based compensation 320,366 841,164
Gain on settlement of accounts payable $ (111,374) (281,911)
Imputed value of services contributed 116,666
Amortization of debt discount $ 129,767 247,631
Changes in operating assets and liabilities:    
Accounts receivable 49,259 206,325
Inventories (38,411) 133,064
Prepaid expenses and other current assets (21,516) (1,059)
Accounts payable - trade (241,915) (485,151)
Accounts payable - related parties (83,452) 623
Accrued expenses and other current liabilities (110,786) (48,867)
Net cash used in operating activities (548,281) (875,769)
Cash flows from investing activities    
Change in restricted cash 50,000 (195,088)
Capital expenditures (6,331) (2,964)
Website development costs (17,972) (114,616)
Net cash provided by (used in) investing activities 25,697 (312,668)
Cash flows from financing activities    
Principal payments on equipment leases payable (64,101) (56,043)
Proceeds from issuance of notes payable 250,000 $ 150,000
Repayment of notes payable (108,911)
Repayment of notes payable - related party $ (49,206) $ (5,000)
Net proceeds from the sale of common stock 1,537,755
Net cash provided by financing activities $ 27,782 1,626,712
Net (decrease) increase in cash (494,802) 438,275
Cash - beginning of period 506,019 67,744
Cash - end of period 11,217 506,019
Cash paid for:    
Interest $ 78,489 $ 86,692
Taxes
Non-cash investing and financing activities:    
Issuance of Series B preferred stock for settlement of accrued dividends $ 298,918 $ 279,380
Cashless exercise of warrants into common stock 95
Warrants issued in connection with notes payable 71,400 $ 36,000
Accrual of contractual dividends on Series B convertible preferred stock $ 319,854 $ 298,918